

# Metabolic Profiling of Immune Responses in Immune-mediated Diseases

NCT04864886

---

**Status** RECRUITING  
**Sponsor** National Institute of Allergy and Infectious Diseases (NIAID)  
**Enrollment** 300 participants

## Key Eligibility Criteria

---

### Inclusion (10)

- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Meets one of the following:
- Has documentation of PID confirmed by genetic evaluation demonstrating a deleterious variant in the gene (or genes) known to be associated with immune deficiency (confirmed PID); or
- Has documented variant of undetermined significance in a gene (or genes) that is predicted to be deleterious in immune function by the investigators OR a clinical history of infections which are more frequent, more chronic, or more severe than normal (suspected PID); or
- Has physician-diagnosed psoriasis; or
- ... and 5 more (see full listing online)

### Exclusion (7)

- An individual who meets any of the following criteria will be excluded from participation in this study:
- Current or prior (within 3 months) anticoagulant or anti-platelet therapy (other than aspirin or non-steroidal anti-inflammatory drugs).
- Current or prior (within 3 months) use of immunomodulatory drugs (eg, chemotherapy, steroids), except if approved by the principal investigator.
- History of keloid formation.
- Pregnancy, lactating, or breastfeeding.
- ... and 2 more (see full listing online)

## Locations (1 total)

---

National Institutes of Health Clinical Center, Bethesda, Maryland, United States